Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 12, 2007

Clinical Data Purchases Protedyne’s Radius Platform

  • Clinical Data’s (www.clda.com) Cogenics division bought Protedyne’s (www.protedyne.com) Radius automation system. “This new equipment is required for the higher throughput studies that our clients are demanding,” points out Robert Bondaryk, Cogenics’ general manager. “This platform strongly supports current tests, such as Familion Long QT, and the continuing rollout of new CLIA sequencing tests launched by Clinical Data's PGxHealth Division.” Radius is a benchtop automation platform designed with a radial arm to provide the highest level of flexibility built to ensure reliability, superior speed, and unmatched precision, says Pete Massaro, CTO of Protedyne.


Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »